Evidence map›Paper›PMID 39339224›Full record

ReviewPharmaceutics2024

Emerging Trends in Dissolving-Microneedle Technology for Antimicrobial Skin-Infection Therapies.

Rui Luo, Huihui Xu, Qiaoni Lin, Jiaying Chi, Tingzhi Liu, Bingrui Jin, Jiayu Ou, Zejun Xu, Tingting Peng, Guilan Quan and 1 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Pharmaceutics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Harnessing Ultrasonic Technologies to TreatMolecules (Basel, Switzerland) · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Rui LuoState Key Laboratory of Bioactive Molecules and Druggability Assessment, Department of Pharmacy, Jinan University, Guangzhou 511436, China.
Huihui XuState Key Laboratory of Bioactive Molecules and Druggability Assessment, Department of Pharmacy, Jinan University, Guangzhou 511436, China.
Qiaoni LinState Key Laboratory of Bioactive Molecules and Druggability Assessment, Department of Pharmacy, Jinan University, Guangzhou 511436, China.
Jiaying ChiState Key Laboratory of Bioactive Molecules and Druggability Assessment, Department of Pharmacy, Jinan University, Guangzhou 511436, China.
Tingzhi LiuState Key Laboratory of Bioactive Molecules and Druggability Assessment, Department of Pharmacy, Jinan University, Guangzhou 511436, China.
Bingrui JinState Key Laboratory of Bioactive Molecules and Druggability Assessment, Department of Pharmacy, Jinan University, Guangzhou 511436, China.
Jiayu OuState Key Laboratory of Bioactive Molecules and Druggability Assessment, Department of Pharmacy, Jinan University, Guangzhou 511436, China.
Zejun XuState Key Laboratory of Bioactive Molecules and Druggability Assessment, Department of Pharmacy, Jinan University, Guangzhou 511436, China.
Tingting PengState Key Laboratory of Bioactive Molecules and Druggability Assessment, Department of Pharmacy, Jinan University, Guangzhou 511436, China.
Guilan QuanState Key Laboratory of Bioactive Molecules and Druggability Assessment, Department of Pharmacy, Jinan University, Guangzhou 511436, China.
Chao LuState Key Laboratory of Bioactive Molecules and Druggability Assessment, Department of Pharmacy, Jinan University, Guangzhou 511436, China.ORCID 0000-0002-2118-8888

Funding

China Postdoctoral Science Foundation 2023M740789Guangdong Basic and Applied Basic Research Foundation 2023A1515110441Guangdong Basic and Applied Basic Research Foundation 2024A1515011248Guangdong Basic and Applied Basic Research Foundation 2024A1515030104Youth Science and Technology Innovation Talent of Guangdong Tezhi Plan 2021TQ060944
6 · The paper itself

Abstract

Skin and soft-tissue infections require significant consideration because of their prolonged treatment duration and propensity to rapidly progress, resulting in severe complications. The primary challenge in their treatment stems from the involvement of drug-resistant microorganisms that can form impermeable biofilms, as well as the possibility of infection extending deep into tissues, thereby complicating drug delivery. Dissolving microneedle patches are an innovative transdermal drug-delivery system that effectively enhances drug penetration through the stratum corneum barrier, thereby increasing drug concentration at the site of infection. They offer highly efficient, safe, and patient-friendly alternatives to conventional topical formulations. This comprehensive review focuses on recent advances and emerging trends in dissolving-microneedle technology for antimicrobial skin-infection therapy. Conventional antibiotic microneedles are compared with those based on emerging antimicrobial agents, such as quorum-sensing inhibitors, antimicrobial peptides, and antimicrobial-matrix materials. The review also highlights the potential of innovative microneedles incorporating chemodynamic, nanoenzyme antimicrobial, photodynamic, and photothermal antibacterial therapies. This review explores the advantages of various antimicrobial therapies and emphasizes the potential of their combined application to improve the efficacy of microneedles. Finally, this review analyzes the druggability of different antimicrobial microneedles and discusses possible future developments.

Indexed as

antimicrobial therapydissolving microneedlesdrug delivery systemsdruggabilityskin infection

Identifiers

PMID39339224
PMCPMC11435303

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.